Dyadic International (DYAI) Net Cash Flow Growth (1y) (2019 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn | 349.49% |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn | -55.11% |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 172.72% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 53.21% |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | 47.11% |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn | -100.75% |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | -2,371.48% |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - | 51.70% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 51.70% |
| Dec 31, 2025 | -320.25% |
| Sep 30, 2025 | 1,593.55% |
| Jun 30, 2025 | 75.40% |
| Mar 31, 2025 | -135.58% |
| Dec 31, 2024 | 166.48% |
| Sep 30, 2024 | -113.61% |
| Jun 30, 2024 | -731.53% |
| Mar 31, 2024 | 599.02% |
| Dec 31, 2023 | 3.59% |
| Sep 30, 2023 | 157.43% |
| Jun 30, 2023 | 81.80% |
| Mar 31, 2023 | 117.43% |
| Dec 31, 2022 | -143.72% |
| Sep 30, 2022 | -728.30% |
| Jun 30, 2022 | -100.04% |
| Mar 31, 2022 | 99.96% |
| Dec 31, 2021 | 272.32% |
| Sep 30, 2021 | -103.27% |
| Jun 30, 2021 | 106,817.67% |